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Heteromultimeric G protein-activated inward recti-
fier K1 (GIRK) channels, abundant in heart and brain,
help to determine the cellular membrane potential as
well as the frequency and duration of electrical im-
pulses. The sequence arginine-glycine-aspartate (RGD),
located extracellularly between the first membrane-
spanning region and the pore, is conserved among all
identified GIRK subunits but is not found in the extra-
cellular domain of any other cloned K1 channels. Many
integrins, which, like channels, are integral membrane
proteins, recognize this RGD sequence on other pro-
teins, usually in the extracellular matrix. We therefore
asked whether GIRK activity might be regulated by di-
rect interaction with integrin. Here, we present evi-
dence that mutation of the RGD site to RGE, particu-
larly on the GIRK4 subunit, decreases or abolishes GIRK
current. Furthermore, wild-type channels can be co-im-
munoprecipitated with integrin. The total cellular
amount of expressed mutant GIRK channel protein is
the same as the wild-type protein; however, the amount
of mutant channel protein that localizes to the plasma
membrane is decreased relative to wild-type, most likely
accounting for the diminished GIRK current detected.
GIRK channels appear to bind directly to integrin and to
require this interaction for proper GIRK channel mem-
brane localization and function.
G protein-activated inward rectifier K1 (GIRK)1 channels
are found in both the heart and the brain, where they are
associated with slowing of the heart rate and suppression of
neuronal firing (1). The channel found in the sinoatrial node
and on atrial myocytes, KACh, is formed from two homologous
channel subunits, GIRK1 (KGA or Kir3.1) and GIRK4 (CIR or
Kir3.4) (2–4). This channel is activated by the release of ace-
tylcholine from the vagus nerve acting on the m2AChR, as well
as by adenosine and other transmitters the receptors of which
activate specific G proteins containing the Gai subunit. The
channel is opened by the direct binding of freed Gbg subunits
(5–9). GIRK channels are part of the larger family of inward
rectifier K1 channels the members of which have similar sub-
unit topology, two or more membrane spanning domains con-
nected by a pore-forming P loop that dips partially into the
membrane. Interestingly, all known GIRK subunits and no
other K1 channels (including other inward rectifier K1 chan-
nels) have a conserved peptide sequence, arginine-glycine-as-
partate (RGD), on their proposed extracellular surface between
the putative first membrane spanning region and the P region
(Fig. 1) (2, 4, 10). These three amino acids form the recognition
sequence for some of the ligands that bind to another class of
membrane proteins, integrins (11). The presence of this amino
acid sequence on GIRKs suggests that these channels may
directly bind to and be modified by integrins.
Integrins are formed from two subunits, a and b, each with
a single transmembrane domain. The extracellular portions of
each subunit are involved in the recognition and binding to
RGD sites on ligands, whereas intracellular portions associate
with cytoskeletal proteins; integrins are thus ideally suited for
roles in signal transduction, and complexes of intracellular
signaling molecules and their activities are found associated
with integrins. Their functions are diverse and include cell
adhesion, migration, polarity, survival, growth, proliferation,
differentiation, and alteration of gene expression (11–14). The
cycling of integrin to and from the plasma membrane is impor-
tant to its function in many cells and regulates the function of
other molecules that bind to it (15–17). Integrin has also been
specifically associated with nervous system functions (18), such
as the level of hippocampal neuronal excitability (19), stretch-
induced neurotransmitter release (20), short and long term
memory (21), and neurite outgrowth (22).
Could some actions of GIRK channels in excitable tissues be
mediated by interaction with integrin and vice versa? We have
begun to address this question by asking whether the function
of GIRK channels is affected by a direct binding interaction
with integrin. The results reported here address this question.
EXPERIMENTAL PROCEDURES
Peptide and Antibodies—GRGDSP peptide was made at the Biopoly-
mer Synthesis Facility of the Beckman Institute at the California
Institute of Technology. The GIRK1 antibody was raised in rabbits
against a peptide from the C terminus of rat GIRK1 (23). The GIRK4
antibodies were a rabbit antibody against a rat GIRK4 N-terminal
peptide (Upstate Biotechnology; no longer available) and a guinea pig
antibody against a mouse C-terminal peptide (a generous gift of Dr.
Florian Lesage, Institut de Pharmacologie Moleculaire et Cellulaire
(24)). The integrin antibodies included 8C8, a mouse monoclonal anti-
Xenopus b1 integrin antibody (Developmental Studies Hybridoma
Bank), and a rabbit antibody raised against the C terminus of chick b1
integrin (a generous gift of Dr. Richard Hynes, MIT (25)). The pan-Trk
antibody was TrkC-14, raised in rabbits against the C terminus of
human TrkA precursor (Santa Cruz Biotech).
Mutagenesis—The GIRK1 and GIRK4 cDNAs were both cloned into
pMXT, a derivative of pBluescript containing b globin sequences known
to stabilize transcripts in oocytes (26). Oligonucleotides containing a
mismatch to these WT DNA templates were designed and used in PCR
amplification to generate a mutant cDNA in which the RGD site of the
protein was changed to RGE (codons CGG GGC GAA in GIRK1 and
CGA GGT GAA in GIRK4). Full-length mutant clones were isolated and
screened by dideoxy terminator sequencing. For CHO cell transfection,
the WT GIRK4 construct was in pCDNA3; WT GIRK1 and mutant
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GIRK1 and GIRK4 cDNAs were subcloned into pCDNA3.1 (Invitrogen).
Oocytes and Mammalian Cells—Xenopus laevis oocytes were pre-
pared and maintained essentially as described (27). RNA was tran-
scribed in vitro (mMessage Machine, Ambion) by T3 or T7 RNA polym-
erase for the GIRK subunits in pMXT and the m2AChR in pGEM,
respectively. For most electrophysiological studies, oocytes were in-
jected with 50 nl containing 1 ng of each of the WT GIRK1 and GIRK4
subunit cRNAs and the m2AChR cRNA in H2O. However, in electro-
physiological experiments with the GIRK1*/GIRK4* channel, 10 ng of
each GIRK subunit cRNA was injected. For experiments with the
GRGDSP peptide, 100 mM peptide was included in the bathing medium
just after injection of channel RNA into the oocytes and in all recording
solutions. Electrophysiological recordings were performed 1–4 days
after injection. For biochemical experiments, oocytes were injected with
5–10 ng of each GIRK subunit cRNA and assayed 2–4 days after
injection. For metabolic labeling with [35S]methionine, oocytes were
injected with 50 nl containing the GIRK cRNAs (5–10 ng/oocyte) as well
as 0.25 mCi [35S]methionine (Amersham Pharmacia Biotech).
CHO cells were maintained in Ham’s F-12 with 10% fetal bovine
serum, 1 mM glutamine, 100 units/ml penicillin, and 100 mg/ml strep-
tomycin under an atmosphere of 5% CO2 at 37 °C. For recording from
transfected CHO cells, the LipofectAMINE reagent (Life Technologies,
Inc.) was used to cotransfect a combination of WT or mutant GIRK1 and
GIRK4 and m2AChR (0.5 mg each/35-mm dish) and green fluorescent
protein (pGreen Lantern, 0.125 mg/35-mm dish, Life Technologies, Inc.)
DNA in serum-free medium, and recording was performed 24 h after
transfection (28).
Whole Cell Recording—Two-electrode voltage clamp recording was
performed on X. laevis oocytes using an Axoclamp 2A amplifier (Axon
Instruments). Data acquisition, voltage command signals, and analysis
were executed using pCLAMP software (Axon). The initial recording
solution was a high Na1 solution containing 98 mM NaCl, 1 mM MgCl2,
5 mM HEPES, pH 7.5. To record inward GIRK currents, the solution
was changed to either a 98 K1 or a 20 K1 solution similar to the high
Na1 except that the NaCl was either fully replaced by KCl or partially
replaced by 20 mM KCl. To activate the GIRK currents via the m2AChR,
1 mM ACh was included. In order to block GIRK currents, 300 mM Ba21
was also included. GIRK currents were recorded using a voltage ramp
from 280 to 130 mV from a holding potential of 280 mV. Voltage jumps
from the 280 mV holding potential to 0 mV and then to 2100 mV were
also performed in order to examine the activation kinetics of the GIRK
channels.
Whole cell patch-clamp recording from CHO cells was performed
using an Axopatch 1D amplifier (Axon Instruments). 3–5 MV electrodes
were used to form high resistance seals on the cell membranes. The
recording pipette solution contained 144 mM KCl, 2 mM MgCl2, 5 mM
HEPES, 5 mM EGTA, 4 mM ATP, and 0.2 mM GTP, pH 7.2. Initial
recording was performed in an external solution of low K1 containing
140 mM NaCl, 30 mM D-glucose, 5.4 mM KCl, 1 mM MgCl2, 2 mM CaCl2,
and 10 mM HEPES, pH 7.4. The 98 K1 solution, with or without 5 mM
ACh, was applied from movable tubes near the cell and contained 120
mM NaCl, 30 mM D-glucose, 25 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM
HEPES, pH 7.4.
Coimmunoprecipitation—For coimmunoprecipitation from whole oo-
cytes, 10–30 oocytes were homogenized in 10 ml/oocyte of lysis buffer
(150 mM NaCl, 1 mM MgCl2, 50 mM Tris, pH 7.6, 1% CHAPS, 2 mM
aprotinin, 2 mM pepstatin, 2 mM leupeptin, 2 mM iodoacetamide, 1 mM
N-ethylmaleimide, and 2 mM phenylmethylsulfonyl fluoride) for 10 min
on ice. Insoluble material was removed by 1 min of centrifugation at
16,000 3 g, 4 °C. The supernatant was precleared by incubation at 4 °C
with protein G-Sepharose (Amersham Pharmacia Biotech) for 1 h.
Sepharose was removed by 20 s of centrifugation in a Picofuge (Strat-
agene). Primary antibody (GIRK1, GIRK4, anti-chick integrin b1, or
pan-Trk) and protein G-Sepharose were added to the precleared lysate
and incubated for 3 h at 4 °C and pelleted. Immunoprecipitates were
washed 4 times with 1 ml of lysis buffer, heated at 95 °C for 5 min in 23
nonreducing Laemmli sample buffer, and electrophoresed on SDS-poly-
acrylamide gels (7% polyacrylamide for integrin and 10% for GIRKs).
Plasma Membrane Preparations—Plasma membranes were sepa-
rated mechanically, with modifications from a previously described
procedure (29). Defolliculated oocytes were incubated for 10 min in
ice-cold hypotonic solution (5 mM NaCl, 5 mM Hepes, 0.07% SDS, con-
taining protease inhibitors as described above). Plasma membranes
together with vitelline membranes (extracellular collagen-like matrix)
were removed manually with fine forceps. Six plasma membranes from
each group were solubilized in SDS loading sample buffer, heated at
95 °C for 5 min, and analyzed by 10% SDS-polyacrylamide gel
electrophoresis.
Western Blots and Autoradiography—Proteins were separated on 7
or 10% SDS-polyacrylamide gels to visualize the integrin and the GIRK
channels, respectively (Protean System, Bio-Rad). The proteins were
then transferred to nitrocellulose membranes and visualized with
Western blots or autoradiography in the following manner. For Western
blots, membranes were blocked with 5% nonfat dried milk in PBS with
0.1% Tween 20 for 1 h. After blocking, membranes were incubated with
appropriate primary antibody for 3 h at room temperature, washed in
blocking solution diluted 1:1 with PBS, and then incubated with horse-
radish peroxidase-conjugated anti-mouse or anti-rabbit secondary an-
tibodies for 1 h. Primary and secondary antibodies were diluted in the
blocking solution. Proteins were visualized using an ECL detection
system (Amersham Pharmacia Biotech). Using antibodies from differ-
ent species for the immunoprecipitation and immunoblot minimized
their tendency to obscure the proteins of interest on Western blots of
immunoprecipitated proteins. For the same reason, when visualization
of immunoprecipitated GIRK proteins expressed in oocytes was desired,
[35S]methionine was coinjected to allow for radioactive labeling of the
channel proteins during synthesis and autoradiographic visualization
of the proteins on nitrocellulose blots. Integrins were not labeled de-
tectably by [35S]methionine because integrins are synthesized through-
out oogenesis and before injection of the mRNA-[35S]methionine mix-
ture, in contrast to GIRK1 and GIRK4, which are fully labeled because
synthesis occurs only during the 2–4 days after injection of the
mRNA-[35S]methionine mixture. Western blots with the 8C8 antibody
used nonreducing conditions, because this antibody recognizes the non-
reduced form of integrin.
RESULTS
Mutagenesis Shows That the RGD Site Is Required for Func-
tional GIRK Activity—We used site-directed mutagenesis to
alter the RGD site on both the GIRK1 and GIRK4 subunits.
The mutations, converting the aspartate to glutamate, change
only the size of the amino acid side chains. Thus, they are
unlikely to change channel expression or assembly while dis-
rupting the integrin binding site. An asterisk is used to indicate
subunits containing the RGE mutation.
GIRK1/GIRK4 channel activity was assessed after co-injec-
tion of mRNA for the m2AChR, GIRK1, and GIRK4 into X.
laevis oocytes. GIRK current was elicited with 1 mM ACh, which
stimulates the expressed m2AChR, activating endogenous Gi to
liberate Gbg, which in turn activates the expressed GIRK1/
GIRK4 heteromultimeric channels. In Figs. 2 and 3a, the ACh-
evoked GIRK currents from various combinations of mutant
and WT GIRK subunits are compared. Similar quantities of
RNA were coinjected into the oocytes, except for the GIRK1*/
GIRK4* construct, which had 10-fold more RNA, in the follow-
ing combinations: GIRK1/GIRK4, GIRK1*/GIRK4, GIRK1/
GIRK4*, and GIRK1*/GIRK4*. Recordings were made 2 days
after injection. The data show that the GIRK1*/GIRK4, GIRK1/
GIRK4*, and double mutant GIRK1*/GIRK4* combinations
produced ,25%, ,10%, and ,2% the current of WT channels,
FIG. 1. Schematic diagram of the GIRK subunits showing the
location of the conserved RGD sequence.
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respectively (currents at 280 mV are directly compared in Figs.
2a and 3a). The amount of GIRK1*/GIRK4 current continued to
increase on days 3 and 4 after injection and reached levels
comparable to those measured on day 1 or 2 for WT channels.
In contrast, after waiting several more days for expression, we
never observed large currents from the GIRK1/GIRK4* or the
double mutant channels. GIRK channels display activation in
the absence of agonists in heterologous expression systems;
these basal currents were decreased to the same extent as the
ACh-evoked currents (Fig. 2a). Even injecting larger quantities
of RNA for mutant subunits (shown in Figs. 2 and 3a for the
GIRK1*/GIRK4* mutant) or injecting Gb1g2 mRNA directly (2,
30) (data not shown) did not rescue channel function. No obvi-
ous difference in the extent of inward rectification or voltage-
jump kinetics of the currents was observed for mutant subunits
(Fig. 2, b and c). These data show that mutation of the RGD site
on the channel to RGE disrupts GIRK currents in oocytes,
consistent with the idea that the channel and endogenous
oocyte integrin interact. The GIRK4 subunit, furthermore,
seems to have a more important role in this interaction than
the GIRK1 subunit. Interestingly, although integrin commonly
interacts with ligands such as extracellular matrix proteins or
with molecules found on other cells, the interaction of integrin
with the GIRK channel seems to be occurring on the same cell
(11).
WT and mutant channels were also expressed in CHO cells,
which, unlike oocytes, express no endogenous GIRK subunits
(31). Cells were transfected with DNA for the channel,
m2AChR, and green fluorescent protein, which provided a vis-
ual indicator of cotransfected cells. ACh-evoked currents were
compared beginning 24 h after transfection (Fig. 3b). In the
CHO cells, the GIRK1*/GIRK4 construct expressed as well as
did the WT construct. Strikingly, any construct containing the
GIRK4* subunit, either as GIRK1/GIRK4* or GIRK1*/GIRK4*,
gave no detectable current. Thus, the relative importance of the
GIRK4 subunit in the possible interaction of GIRK and integrin
is revealed more dramatically by expression in the CHO cell
system.
An Externally Applied RGD Peptide Does Not Detectably
Alter GIRK Function—Externally applied RGD-containing
peptides are often used to compete for an interaction of integrin
with its ligand, disrupting integrin activity and thus implicat-
ing a role for integrin in various cellular phenomena (20, 22).
We performed similar experiments with expressed GIRK chan-
nels. GIRK activity was again observed after co-injection of
mRNA for the m2AChR, GIRK1, and GIRK4 into X. laevis
oocytes. In Fig. 4, ACh-evoked GIRK currents from oocytes
incubated in the absence or presence of 100 mM GRGDSP were
compared 1 day after RNA injection. Peptide was added to the
oocyte bathing medium immediately following RNA injection
and was included in all of the recording solutions. Desensitiza-
tion was measured as the fractional ACh induced current re-
maining 5 min after the peak current. The peptide produced no
dramatic change in the peak amplitude (Fig. 4a) or desensiti-
zation (Fig. 4b) of ACh-evoked currents.
GIRK Channels Bind Directly to Integrins—That the GIRK
FIG. 2. ACh-evoked currents from X. laevis oocytes expressing normal and RGD3RGE mutated GIRK channels 2 days after
injection with RNA for various combinations of WT and mutant GIRK subunits and the m2AChR. The asterisk indicates subunits
containing the RGE mutation. a, recordings after application of high Na1 solution (NaCl), 20 K1 solution (KCl), 20 K1 solution with 1 mM ACh
(ACh), and 20 K1 solution with 1 mM ACh and 300 mM Ba21 (Ba). b, ramps from 280 to 130 mV. c, voltage jump relaxations for a step from 0 to
2100 mV. Waveforms have been scaled to superimpose. GIRK1*/GIRK4* currents are not included because they are too small for meaningful
normalization.
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channel binds to integrin is consistent with the mutagenesis
studies described above (Figs. 2 and 3), but the lack of RGD
peptide effects produced no further evidence for a direct inter-
action. The lack of effect with the RGD-containing peptide does
not rule out an interaction between GIRKs and integrins, be-
cause the peptide may not be able to access the GIRK-integrin
binding site or may not form a structure that competes effec-
tively for a GIRK-integrin interaction. We initiated a series of
studies to co-immunoprecipitate the channel and endogenous
integrin from detergent-solubilized whole oocytes, with detec-
tion by Western blots and by autoradiography for the GIRK
channels labeled radioactively during expression in oocytes.
Fig. 5, a and b, shows that the GIRK channel and integrin were
co-immunoprecipitated from oocytes with antibodies specific
for either protein. An anti-chick integrin antibody, against a
highly conserved portion of the integrin b1 subunit, immuno-
precipitated the radiolabeled WT GIRK1 and GIRK4 subunits,
as did the anti-GIRK1 antibody (Fig. 5a, autoradiogram). Data
from cells expressing either the GIRK1 or GIRK4 subunit (im-
munoprecipitated with the anti-GIRK1 and GIRK4 antibodies,
respectively) confirm that the GIRK1 protein runs as a doublet
of about 56–58 kDa and that the GIRK4 protein runs as a
major band of about 45 kDa. Western blots performed with an
anti-Xenopus b1 integrin antibody revealed that the anti-
GIRK1 antibody immunoprecipitated the endogenous oocyte
integrin from cells expressing both WT GIRK subunits, as did
the anti-chick integrin antibody (Fig. 5b, immunoblot). Integrin
b1 runs as a doublet due to differentially glycosylated forms
(32). A control antibody that binds to neither integrin nor the
channel, pan-Trk, immunoprecipitated neither the channel nor
integrin, ruling out the possibility that these proteins bound
nonspecifically to the Sepharose used during immunoprecipi-
tation. These studies show directly that GIRK and integrin do
bind to each other when the channel is expressed in heterolo-
gous cells.
We performed similar co-immunoprecipitation experiments
with the mutant GIRK subunits expressed in oocytes. If these
mutations disrupt the binding of integrin to the GIRK channel,
we would expect that the mutant channels and integrin would
not co-immunoprecipitate. As shown in Fig. 5a, although the
anti-chick integrin antibody immunoprecipitated both coex-
pressed WT GIRK channel subunits, it did not precipitate
FIG. 3. Direct comparison of ACh-evoked mean currents 6 S.E.
for WT and RGD3RGE mutated GIRK channels. a, currents from
oocytes measured at 280 mV; each column represents measurements
from 4 or 5 oocytes as described in Fig. 2. b, currents from CHO cells
measured at 2120 mV 24 h after transfection for the m2AChR and for
various combinations of WT and mutant GIRK subunits (0.5 mg of DNA
from each construct/dish). Each column represents measurements from
3–5 cells.
FIG. 4. ACh-evoked currents measured in 98 K1 solution 1 day
after GIRK channel and m2AChr RNA injection into X. laevis
oocytes in the absence and presence of extracellular 100 mM
GRGDSP peptide. a, mean amplitude 6 S.E. (four oocytes each) of
peak ACh-induced current at 280 mV. b, mean desensitization 6 S.E.
(four oocytes each). Desensitization was measured as the fractional
ACh-induced current remaining 5 min after the peak current. The data
are representative of experiments on three oocyte batches and from two
separate syntheses of peptide.
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either subunit of the GIRK1*/GIRK4* channel. Correspond-
ingly, Fig. 5b demonstrates that although the anti-GIRK1 an-
tibody immunoprecipitated the integrin from cells expressing
WT channels, it did not immunoprecipitate integrin from cells
expressing the double mutant channels. As expected, the bind-
ing of the mutant channel to integrin appears to be disrupted,
and this disruption apparently eliminates its ACh-activated
current.
Mutant Channel Expression Is Not Altered, but Plasma Mem-
brane Localization Is Altered—Fig. 6, a and b, shows a compar-
ison of the oocyte expression levels of GIRK channels composed
of mutant versus WT subunits. After the oocyte was lysed,
channel subunits were detected by Western analysis with an-
tibodies specific to GIRK1 and GIRK4 (Fig. 6, a and b, respec-
tively). When WT or mutant subunits were expressed in oo-
cytes, the total amount of each channel subunit protein was
similar.
Although roughly equal total amounts of protein were ex-
pressed for each channel combination, we found that less mu-
tant channel protein reached the plasma membrane. The im-
munoblots in Fig. 6, c and d, compare the GIRK1 and GIRK4
channel subunit protein contained in manually isolated (29)
plasma membranes of oocytes expressing WT and various mu-
tant GIRK combinations. When either WT GIRK subunit was
replaced by a mutated subunit, less GIRK1 (Fig. 6c) or GIRK4
(Fig. 6d) subunit reached the plasma membrane, even though
the total cellular expression levels of the mutant proteins are
the same as WT. The diminution in plasma membrane expres-
sion was greatest when both GIRK1 and GIRK4 subunits were
replaced by the mutated subunit and was particularly striking
for the more slowly migrating band corresponding to the gly-
cosylated GIRK protein. In other experiments not shown, we
injected oocytes with [35S]methionine as they expressed normal
and double mutant GIRK channels, manually isolated the
membranes, and used the GIRK1 antibody to immunoprecipi-
tate the GIRK channel protein. We measured .3-fold and
.10-fold less radioactivity in the unglycosylated and glycosy-
lated bands, respectively, for the double mutant GIRK chan-
nels. Interestingly, when we purified a plasma membrane frac-
tion by isolating various pools of oocyte membranes from a total
membrane preparation on sucrose gradients (33, 34), we ob-
served no difference in the amount of mutant and WT channel
protein, possibly because the mutant GIRK proteins may reach
a vesicle pool that cofractionates with the plasma membrane.
DISCUSSION
Direct Binding of GIRK to Integrin Is Required for GIRK
Channel Function—The data presented here support the idea
that the GIRK channel binds to integrin directly, that mutation
of the integrin recognition site on the channel eliminates this
binding, and that without this binding, the GIRK current de-
creases or is eliminated. Evidence for this view is provided by
the observations that GIRK RGD 3 RGE mutants have dis-
rupted function and that WT but not RGD 3 RGE mutants
co-immunoprecipitate from total oocyte lysate. Expression of
the mutant channel protein is comparable to that of WT, but
decreased quantities of mutant GIRK protein reach the plasma
membrane (Fig. 6). Most likely, the decreased quantity of mu-
tant channel protein in the plasma membrane explains most if
not all of the decreased current for mutant-containing constructs.
The RGD 3 RGE mutation preserves the charge of the
native amino acid and is thus unlikely to cause a major disrup-
tion of protein folding or membrane insertion. Recent atomic-
scale crystallographic data on a Streptomyces lividans K1
channel suggest that this region of the channel is part of an
extracellular “turret” on the channel (35), conceivably poised to
interact with the extracellular domain of an integrin molecule.
Although such a mutation would be expected to destroy func-
tion if the aspartate residue interacts directly with permeant
K1 ions, the structural data also argue against this possibility.
Interestingly, although the RGD sequence is preserved in
GIRK channels, it diverges slightly in other inward rectifiers,
often forming an HGD motif, but the aspartate residue of the
motif is well conserved throughout the family of inward recti-
fiers. The residue is clearly important in Kir1.1 (ROMK1), for
instance, because an aspartate-to-histidine mutation produces
a nonfunctional channel in one allele of Bartter syndrome (36).
This conservation is consistent with the idea that other inward
FIG. 5. Co-immunoprecipitation of GIRK channels and endogenous integrin from GIRK1/GIRK4 RNA-injected oocytes. a, GIRK1
and GIRK4 subunit protein visualized autoradiographically from uninjected oocytes or oocytes injected with GIRK1/GIRK4, GIRK1*/GIRK4*,
GIRK1, or GIRK4 (blot representative of six experiments). All cells were also injected with [35S]methionine. Protein in lanes labeled Integrin was
immunoprecipitated with the integrin anti-chick antibody from cells injected with no channel RNA (none), GIRK1/GIRK4 channel RNA (G1/G4),
or GIRK1*/GIRK4* channel RNA (G1*/G4*). Protein in the lane labeled Trk was eluted after pan-Trk antibody immunoprecipitation from cells
injected with GIRK1/GIRK4 RNA. Protein in the lanes labeled GIRK1 was immunoprecipitated with anti-GIRK1 antibody from cells injected with
GIRK1/GIRK4 channel RNA (G1/G4) or GIRK1 RNA only (G1), showing that the GIRK1 protein runs as a clearly identifiable doublet at about
56–58 kDa. Protein in the lane labeled GIRK4 was eluted after anti-GIRK4 antibody immunoprecipitation from cells injected with GIRK4 RNA
only, showing that the GIRK4 protein runs as a major band at about 45 kDa. Protein was from 30 oocytes each for lanes Integrin and Trk and from
10 oocytes each for GIRK1 and GIRK4. b, endogenous integrin protein visualized by Western blotting with the 8C8 antibody from uninjected
oocytes or oocytes injected with GIRK1/GIRK4 or GIRK1*/GIRK4* RNA (blot representative of two experiments). Protein in lanes labeled Integrin
was integrin immunoprecipitated with the integrin anti-chick antibody from cells injected with no RNA (none), GIRK1/GIRK4 RNA (G1/G4), or
GIRK1*/GIRK4* RNA (G1*/G4*). Trk, absence of integrin in eluate after pan-Trk antibody immunoprecipitation. Protein in lanes labeled GIRK1
was integrin immunoprecipitated with the anti-GIRK1 antibody from oocytes injected with GIRK1/GIRK4 RNA (G1/G4) or GIRK1*/GIRK4*
(G1*/G4*). Protein was from 10 oocytes for Integrin and Trk and from 20 oocytes for GIRK1.
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rectifiers may also interact with integrin, a notion that we will
explore in the future.
Mechanism of GIRK Regulation by GIRK-Integrin Bind-
ing—We suggest that integrin plays a role in the insertion,
degradation, or stability of GIRK proteins in the plasma mem-
brane. Perhaps the plasma membrane expression of the RGD
3 RGE GIRK mutant subunits decreased because the mutant
subunits cannot bind to integrin in internal membrane com-
partments. If the GIRK-integrin interaction is in an intracel-
lular compartment, this explains how WT channel function is
not altered by incubation with externally applied, RGD-con-
taining peptides.
Integrins themselves cycle in and out of the plasma mem-
branes of neutrophils, and this system is stimulated by chem-
ical signals in a Ca21-dependent manner, allowing changes in
the migration behavior of these cells (15, 37, 38). Integrin
receptors in the plasma membrane of fibroblasts are also reg-
ulated; their stability in the membrane requires the transmis-
sion of adhesion-dependent signals (39). In addition, evidence
exists that integrin regulates the localization of other proteins.
For example, integrin mediates the internalization of adenovi-
rus by binding the virus, which is then endocytosed along with
integrin (17). The degradation of vitronectin is also regulated
by integrin in a similar manner, requiring the prior activation
of protein kinase C (16, 40).
Integrins, particularly those including the integrin b1 sub-
unit that binds with GIRK in our experiments, are associated
with the cytoskeleton via direct interactions with talin, paxil-
lin, tensin, and possibly other cytoskeletal proteins (12). There-
fore, the integrin-GIRK interaction may link the channel to the
cytoskeleton. Several other channels have links to the cytoskel-
eton (41–47), and previous studies show that the actin cy-
toskeleton helps to stabilize some inward rectifiers (48). Me-
chanical stress, presumably transmitted via cytoskeletal ele-
ments, affects both the integrin-mediated transduction path-
way (49) and GIRK activation (50).
It is also possible that integrin may mediate intracellular
signals that regulate GIRK plasma membrane localization.
Integrin intracellular signaling has been associated with tyro-
sine kinases, including src and focal adhesion kinase, and small
GTPases, especially rho. Many of these signaling molecules are
associated with integrin in signaling complexes, which are in
turn ultimately linked to the cytoskeleton. Focal adhesion ki-
nase also interacts with phosphatidylinositol 3-kinase, of inter-
est considering that phosphoinositides may be required for
GIRK activation (51, 52). Integrin-mediated signaling has also
been associated with gene activation and the mitogen-activated
protein kinase pathway (12). It is conceivable that one of these
transduction pathways also modifies GIRK localization by ei-
ther modifying its exocytosis, stability in the plasma mem-
brane, or endocytosis.
Possible Sequelae Involving Integrin Signaling—It is not yet
known whether the possible direct interaction between GIRK
channels and integrin affects signaling by integrin itself via
one the signal transduction pathways associated with the C-
terminal cytoplasmic regions of the integrin molecule. Neurite
formation in neuroblastoma cell lines has been associated with
integrin, with the activation of an inward rectifier K1 channel,
and with tyrosine phosphorylation (22, 53). Mechanosensitive
processes, including stretch-induced release of neurotransmit-
ter (20), have also been associated with integrin function. GIRK
channels are mechanosensitive (50), raising the possibility that
GIRK and integrin may simultaneously be involved in mech-
anosensitive processes. Further studies may reveal details of
the mechanism and physiological relevance of the GIRK-inte-
grin interaction suggested by our data.
FIG. 6. a and b, total cellular GIRK subunit protein from various combinations of WT and mutant GIRK1 and GIRK4 RNA-injected oocytes. Cells
were solubilized with 13 Laemmli sample buffer. Oocytes were injected with 5 ng of each channel subunit RNA. Protein was from 1⁄5 oocyte/lane.
a, GIRK1 subunit protein visualized with Western blots using the anti-GIRK1 antibody. b, GIRK4 subunit protein visualized with Western blots
using the rabbit anti-GIRK4 antibody. c and d, GIRK subunit protein found in plasma membranes manually stripped from oocytes injected with
various combinations of WT and mutant GIRK1 and GIRK4 RNA. Oocytes were injected with 10 ng of each channel subunit RNA. Each lane
contains protein from the plasma membranes of six oocytes. c, GIRK1 subunit protein visualized with anti-GIRK1 antibody. d, GIRK4 subunit
protein visualized with the guinea pig anti-GIRK4 antibody.
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